<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Failure To Respond to an Abbreviated New Drug Application Complete Response Letter Within the Regulatory Timeframe; Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Failure To Respond to an Abbreviated New Drug Application Complete Response Letter Within the Regulatory Timeframe; Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2022-07-25 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Failure To Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe." This guidance is intended to assist applicants in responding to complete response letters (CRLs) to abbreviated new drug applications (ANDAs) submitted to FDA under the Federal Food, Drug, and Cosmetic Act (FD&C Act). This guidance provides information and recommendations regarding poten...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2022-15825</p>
    <p><strong>Publication Date:</strong> 2022-07-25</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/07/25/2022-15825/failure-to-respond-to-an-abbreviated-new-drug-application-complete-response-letter-within-the">https://www.federalregister.gov/documents/2022/07/25/2022-15825/failure-to-respond-to-an-abbreviated-new-drug-application-complete-response-letter-within-the</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-15825</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
